Medications for Hemophilia A

23 results

  • Afstyla

    (ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT)
    CSL Behring Lengnau AG
    Usage: AFSTYLA is indicated for adults and children with hemophilia A to control bleeding episodes, provide routine prophylaxis to reduce bleeding frequency, and manage perioperative bleeding. It is not indicated for von Willebrand disease treatment.

  • Alhemo (concizumab)

    (concizumab)
    Novo Nordisk
    Usage: Alhemo is indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 12 and older with hemophilia A (factor VIII deficiency with inhibitors) and hemophilia B (factor IX deficiency with inhibitors).

  • Altuviiio

    (Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl)
    Bioverativ Therapeutics Inc.
    Usage: ALTUVIIIO is indicated for adults and children with hemophilia A for routine prophylaxis to reduce bleeding episodes, on-demand treatment, and perioperative bleeding management. It is not intended for treating von Willebrand disease.

  • Desmopressin acetate (desmopressin acetate)

    (Desmopressin Acetate)
    Gland Pharma Limited
    Usage: Desmopressin acetate injection is indicated for managing central diabetes insipidus, temporary polyuria and polydipsia after head trauma, and for hemophilia A and mild to moderate von Willebrand’s disease Type I to maintain hemostasis and reduce bleeding during surgeries and injuries.

  • Desmopressin acetate (desmopressin acetate)

    (Desmopressin acetate)
    Meitheal Pharmaceuticals Inc.
    Usage: Desmopressin Acetate Injection is indicated for managing central diabetes insipidus, temporary polyuria and polydipsia post-head trauma or surgery, hemophilia A, and mild to moderate von Willebrand's disease (Type I). It helps maintain hemostasis and reduce bleeding during surgeries and after injuries. Not effective for nephrogenic diabetes insipidus.

  • Eloctate

    (Antihemophilic Factor (Recombinant), Fc Fusion Protein)
    Bioverativ Therapeutics Inc.
    Usage: ELOCTATE is indicated for adults and children with Hemophilia A for on-demand treatment of bleeding episodes, perioperative management, and routine prophylaxis to reduce bleeding frequency. It is not approved for treating von Willebrand disease.

  • Hympavzi (marstacimab-hncq)

    (marstacimab-hncq)
    Pfizer Laboratories Div Pfizer Inc
    Usage: HYMPAVZI is used for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 12 and older with hemophilia A (factor VIII deficiency) or hemophilia B (factor IX deficiency), both without inhibitors.

  • Nuwiq (antihemophilic factor (recombinant))

    (Antihemophilic Factor (Recombinant))
    Octapharma USA Inc
    Usage: NUWIQ is a recombinant antihemophilic factor indicated for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis in patients with Hemophilia A. It is not intended for treating von Willebrand disease.

  • P32 sodium phosphate (p32 sodium phosphate)

    (P32 Sodium Phosphate)
    AnazaoHealth Corporation
    Usage: P32 chromic phosphate is indicated for intracavitary treatment of peritoneal or pleural effusions from metastatic disease and for interstitial injection in cancer treatment. Additionally, it is used for intraarticular injections in patients with hemophilia.

  • Recombinate (antihemophilic factor recombinant)

    (antihemophilic factor recombinant)
    Takeda Pharmaceuticals America, Inc.
    Usage: RECOMBINATE (Antihemophilic Factor, Recombinant) is indicated for the prevention and control of bleeding episodes in hemophilia A and for perioperative management in these patients. It may also be used in patients with acquired Factor VIII inhibitors below 10 Bethesda Units/mL. Not indicated for von Willebrand's disease.